SUBSCRIBE
SUBSCRIBE
News   FDA

GlaxoSmithKline Gets U.S. Lamictal XR FDA Approval

June 1, 2009 | 
1 min read

Reuters -- GlaxoSmithKline, the world’s second-largest drugmaker, said on Monday that its Lamictal XR epilepsy drug had been approved in the United States.

FDA Approvals
GlaxoSmithKline Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Close-Up Of Medicine Bottles Against Green Background
Opinion
FDA Faces Challenging Decision on Biomarker-Based Label Restrictions
March 10, 2025
 · 
5 min read
 · 
Harpreet Singh
A scientist with pill bottles in front of FDA headquarters
Regulatory
FDA Action Alert: GSK, Alnylam, Sanofi and More
March 10, 2025
 · 
7 min read
 · 
Tristan Manalac
Editorial
FDA Weathers Bait-and-Switch Storm as Staff and Sites Come and Go
March 7, 2025
 · 
3 min read
 · 
Jef Akst
Composite photo collage of hand hold magnifier glass research examine secret object question mark secret isolated on painted background.
Editorial
This Might Be a Moot Point but the FDA’s Priority Review Vouchers Need Transparency
March 7, 2025
 · 
3 min read
 · 
Annalee Armstrong